In February 2023, the US-FDA approved sacituzumab govitecan-hziy for the treatment of patients with unresectable locally progressed or metastatic hormone receptor positive (HR+) and HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer patients who have experienced endocrine-based therapy and at least two more systemic therapies for metastatic disease [6,16]. Here, NR4A1 is linked to breast cancer.